Tear
Allan Tear, Providence, RI US
Patent application number | Description | Published |
---|---|---|
20080208644 | Apparatus and Method for Measuring Service Performance - A method for measuring satisfaction within a service environment including the steps of modeling contractual customer service relationships using a hierarchical composition model with discrete abstract elements, creating and distributing customer perception surveys having questions, wherein the questions are dynamically generated from a computer database based on events within the service environment and element weightings within a hierarchical composition model, collecting and analyzing the customer perception surveys, calculating aggregate measures of customer perception that have statistical reliability, correlating the measures of customer perception to create at least one statistical causality between customer perception and business performance and adjusting the element weights using calculated customer perception measures and statistical correlation measures to refine reliability of future analysis and calculation results. | 08-28-2008 |
Guy Tear, London GB
Patent application number | Description | Published |
---|---|---|
20100233819 | ROBO: A NOVEL FAMILY OF POLYPEPTIDES AND NUCLEIC ACIDS - Robo1 and Robo2 polypeptides may be produced recombinantly from transformed host cells from the disclosed Robo encoding nucleic acids or purified from human cells. The invention provides isolated Robo hybridization probes and primers capable of specifically hybridizing with the disclosed Robo genes, Robo-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry. | 09-16-2010 |
Victoria Jane Tear, Southampton GB
Patent application number | Description | Published |
---|---|---|
20130064792 | THERAPY FOR INFLUENZA LIKE ILLNESS - An agent selected from: (a) interferon-β (IFN-β); (b) an agent that increases IFN-β expression; or (c) a polynucleotide which is capable of expressing (a) or (b); for use in the treatment of individuals with lower respiratory tract illness that has developed during or following an established ILI, wherein said treatment is by airway delivery of said medicament. | 03-14-2013 |